Avidity Biosciences (RNA) said Monday it completed enrollment in the biomarker group in a phase 1/2 trial of delpacibart braxlosiran, or del-brax, in people with facioscapulohumeral muscular dystrophy, a genetic muscle disorder.
The company said 51 participants were enrolled in the biomarker group.
The del-brax biomarker group was designed for a potential accelerated approval in the US, Avidity said, adding it plans to release a regulatory update in Q2.
The company's shares were down 6% in recent trading.
Price: 29.69, Change: -1.91, Percent Change: -6.04
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。